<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02445989</url>
  </required_header>
  <id_info>
    <org_study_id>48663</org_study_id>
    <secondary_id>R01HD077872</secondary_id>
    <nct_id>NCT02445989</nct_id>
  </id_info>
  <brief_title>Effects of Contraceptive Ring on Vaginal Microbiota, HIV Shedding and Local Immunity</brief_title>
  <official_title>Effects of Contraceptive Ring on Vaginal Microbiota, HIV Shedding and Local Immunity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to explore the hypothesis—supported by limited data—that a
      contraceptive vaginal ring (CVR) that is commonly used in the United States, the NuvaRing,
      will enhance women's genital and reproductive health. The investigators propose that this CVR
      will increase the bacteria that help the vaginal environment protect against infection by HIV
      and other STIs, and that in women who already have HIV, use of the CVR will lower the
      quantity of HIV that is shed in the female genital tract.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators objective is to study effects of a contraceptive vaginal ring (CVR)
      containing estrogen and progesterone (NuvaRing) on vaginal bacteria, HIV shedding, and local
      immunity in women. The investigators will build on data that support a favorable effect of
      CVR on vaginal bacteria. Bacterial vaginosis (BV) is found in &gt;50% of women in sub-Saharan
      Africa. BV significantly increases risk of HIV acquisition in, and HIV transmission to male
      partners from, HIV-infected women, genital HIV shedding, and viral set point in infected male
      partners. Pregnancy is also an independent risk for HIV acquisition and transmission.
      Contraception comprises critical biomedical prevention for women with or at risk for HIV.
      Systemic depot progesterone—commonly used throughout Africa—may independently increase risk
      of HIV acquisition and transmission. Hormonal interventions preventing unintended pregnancy
      and promoting a protective vaginal microenvironment could synergistically reduce HIV risk
      especially combined with topical antiretrovirals (ARV). The investigators propose NuvaRing
      use may contribute to reduction in BV, pregnancy prevention, and decreased rates of HIV
      shedding in HIV-infected women. Sustained vaginal delivery of contraceptive and ARV PrEP as
      &quot;multicomponent prevention&quot; is a major focus for scientists but effects on the vaginal
      environment need careful definition before broad implementation.

      Total duration of follow up is no more than 8 months, with 5 months of CVR usage.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantity of L. crispatus determined by species-specific qPCR assay</measure>
    <time_frame>Up to 8 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of bacterial vaginosis during contraceptive ring uses</measure>
    <time_frame>Up to 8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events with CVR use</measure>
    <time_frame>Up to 8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability of CVR to male sex partners of study participants assessed by questionnaire</measure>
    <time_frame>Up to 1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Bacterial Vaginosis</condition>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Cyclic NuvaRing CVR Use</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CVR use for 3 weeks, remove for 1 week, then replace</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuous NuvaRing CVR Use</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CVR use for 4 weeks, then replace</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NuvaRing</intervention_name>
    <description>Provide NuvaRing to women seeking contraception</description>
    <arm_group_label>Cyclic NuvaRing CVR Use</arm_group_label>
    <arm_group_label>Continuous NuvaRing CVR Use</arm_group_label>
    <other_name>Contraceptive vaginal ring</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BV+ by Amsel Criteria

          -  Not intending to become pregnant over the course of the study

          -  If HIV infected, not taking ART

          -  Capable of providing written informed consent

        Exclusion Criteria:

          -  Current pregnancy

          -  Desire/intent to become pregnant over the course of the study

          -  Contraindications to hormonal contraceptive use

          -  Current cigarette smoking if age is older than 35 years

          -  Unable to comprehend consent material because of language barrier or psychological
             difficulty
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeanne M Marrazzo, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thika Clinic</name>
      <address>
        <city>Thika</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
  </location_countries>
  <link>
    <url>http://www.who.int/reproductivehealth/publications/family_planning/HC-and-HIV-2017/en/</url>
    <description>WHO Hormonal contraceptive eligibility for women at high risk of HIV</description>
  </link>
  <link>
    <url>http://www.who.int/reproductivehealth/publications/family_planning/Ex-Summ-MEC-5/en/</url>
    <description>Medical Eligibility Criteria for contraceptive use - Executive Summary</description>
  </link>
  <reference>
    <citation>Polis CB, Curtis KM. Use of hormonal contraceptives and HIV acquisition in women: a systematic review of the epidemiological evidence. Lancet Infect Dis. 2013 Sep;13(9):797-808. doi: 10.1016/S1473-3099(13)70155-5. Epub 2013 Jul 19. Review.</citation>
    <PMID>23871397</PMID>
  </reference>
  <reference>
    <citation>van der Straten A, Montgomery ET, Cheng H, Wegner L, Masenga G, von Mollendorf C, Bekker L, Ganesh S, Young K, Romano J, Nel A, Woodsong C. High acceptability of a vaginal ring intended as a microbicide delivery method for HIV prevention in African women. AIDS Behav. 2012 Oct;16(7):1775-86.</citation>
    <PMID>22644068</PMID>
  </reference>
  <reference>
    <citation>Kiser PF, Johnson TJ, Clark JT. State of the art in intravaginal ring technology for topical prophylaxis of HIV infection. AIDS Rev. 2012 Jan-Mar;14(1):62-77. Review.</citation>
    <PMID>22297505</PMID>
  </reference>
  <reference>
    <citation>Marrazzo JM, Martin DH, Watts DH, Schulte J, Sobel JD, Hillier SL, Deal C, Fredricks DN. Bacterial vaginosis: identifying research gaps proceedings of a workshop sponsored by DHHS/NIH/NIAID. Sex Transm Dis. 2010 Dec;37(12):732-44. doi: 10.1097/OLQ.0b013e3181fbbc95.</citation>
    <PMID>21068695</PMID>
  </reference>
  <reference>
    <citation>Atashili J, Poole C, Ndumbe PM, Adimora AA, Smith JS. Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS. 2008 Jul 31;22(12):1493-501. doi: 10.1097/QAD.0b013e3283021a37. Review.</citation>
    <PMID>18614873</PMID>
  </reference>
  <reference>
    <citation>Cohen CR, Lingappa JR, Baeten JM, Ngayo MO, Spiegel CA, Hong T, Donnell D, Celum C, Kapiga S, Delany S, Bukusi EA. Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples. PLoS Med. 2012;9(6):e1001251. doi: 10.1371/journal.pmed.1001251. Epub 2012 Jun 26.</citation>
    <PMID>22745608</PMID>
  </reference>
  <reference>
    <citation>Veres S, Miller L, Burington B. A comparison between the vaginal ring and oral contraceptives. Obstet Gynecol. 2004 Sep;104(3):555-63.</citation>
    <PMID>15339769</PMID>
  </reference>
  <reference>
    <citation>Ahrendt HJ, Nisand I, Bastianelli C, Gómez MA, Gemzell-Danielsson K, Urdl W, Karskov B, Oeyen L, Bitzer J, Page G, Milsom I. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone. Contraception. 2006 Dec;74(6):451-7. Epub 2006 Sep 27.</citation>
    <PMID>17157101</PMID>
  </reference>
  <reference>
    <citation>Mugo NR, Heffron R, Donnell D, Wald A, Were EO, Rees H, Celum C, Kiarie JN, Cohen CR, Kayintekore K, Baeten JM; Partners in Prevention HSV/HIV Transmission Study Team. Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1-serodiscordant couples. AIDS. 2011 Sep 24;25(15):1887-95. doi: 10.1097/QAD.0b013e32834a9338.</citation>
    <PMID>21785321</PMID>
  </reference>
  <reference>
    <citation>Taha TE, James MM, Hoover DR, Sun J, Laeyendecker O, Mullis CE, Kumwenda JJ, Lingappa JR, Auvert B, Morrison CS, Mofensen LM, Taylor A, Fowler MG, Kumenda NI, Eshleman SH. Association of recent HIV infection and in-utero HIV-1 transmission. AIDS. 2011 Jul 17;25(11):1357-64. doi: 10.1097/QAD.0b013e3283489d45.</citation>
    <PMID>21572305</PMID>
  </reference>
  <reference>
    <citation>Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, de Bruyn G, Nakku-Joloba E, Ngure K, Kiarie J, Coombs RW, Baeten JM; Partners in Prevention HSV/HIV Transmission Study Team. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis. 2012 Jan;12(1):19-26. doi: 10.1016/S1473-3099(11)70247-X. Epub 2011 Oct 3. Erratum in: Lancet Infect Dis. 2012 Feb;12(2):98.</citation>
    <PMID>21975269</PMID>
  </reference>
  <reference>
    <citation>Mugwanya K, Baeten JM, Mugo NR, Irungu E, Ngure K, Celum C. High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial. J Infect Dis. 2011 Dec 15;204(12):1912-7. doi: 10.1093/infdis/jir649. Epub 2011 Oct 12.</citation>
    <PMID>21998479</PMID>
  </reference>
  <reference>
    <citation>Marrazzo JM, Thomas KK, Fiedler TL, Ringwood K, Fredricks DN. Relationship of specific vaginal bacteria and bacterial vaginosis treatment failure in women who have sex with women. Ann Intern Med. 2008 Jul 1;149(1):20-8.</citation>
    <PMID>18591634</PMID>
  </reference>
  <reference>
    <citation>Baeten JM, Kahle E, Lingappa JR, Coombs RW, Delany-Moretlwe S, Nakku-Joloba E, Mugo NR, Wald A, Corey L, Donnell D, Campbell MS, Mullins JI, Celum C; Partners in Prevention HSV/HIV Transmission Study Team. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med. 2011 Apr 6;3(77):77ra29. doi: 10.1126/scitranslmed.3001888.</citation>
    <PMID>21471433</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2015</study_first_submitted>
  <study_first_submitted_qc>May 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2015</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Jeanne Marrazzo</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Contraceptive Vaginal Ring</keyword>
  <keyword>Bacterial Vaginosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginal Diseases</mesh_term>
    <mesh_term>Vaginosis, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Desogestrel</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

